Ranabaxy pharama copy
Download as pptx, pdf1 like1,504 views
Ranbaxy is India's largest pharmaceutical company with a global presence in 46 countries. It has a mission to become a research-based international pharmaceutical company. Ranbaxy has over 1,400 R&D personnel and is the highest R&D spender in the industry. It focuses on increasing momentum in generics through organic and inorganic growth. Ranbaxy's top products include Simvastatin for cholesterol and Amoxicillin/Clavulanate potassium for bacterial infections. It is currently the second largest player in the Indian market and achieved sales of $1.5 billion globally in 2009.
1 of 16
Downloaded 109 times
Ad
Recommended
Sun pharma Industries limited at a Glance
Sun pharma Industries limited at a GlanceMithlesh Jha
油
Sun Pharmaceutical Industries, founded in 1983 and based in Mumbai, is a leading global generic pharmaceutical company with a presence in over 150 markets and a workforce of 32,700 employees. The company achieved significant financial growth, reporting a global revenue of $4.5 billion for the fiscal year 2014-2015 and notable rankings in various therapeutic sectors. Key acquisitions, including Ranbaxy Laboratories, have positioned Sun Pharma as the largest pharma company in India and the fifth largest globally.Presentation1.pptxdilip shanghvi
Presentation1.pptxdilip shanghviKaran Patel
油
Dilip Shanghvi is the founder and managing director of Sun Pharmaceuticals, which he started in 1982 with Rs. 10,000 capital. Under his leadership, Sun Pharmaceuticals has grown to become India's largest drugmaker and most valuable pharmaceutical company. Shanghvi launched his career helping his father's wholesale drugs business and realized he could manufacture his own drugs. Through strategic acquisitions over the decades, Sun Pharmaceuticals now has a global presence and Shanghvi has a net worth of over $18 billion, making him one of Asia's richest self-made billionaires.SunPharma Ranbaxy Acquisition
SunPharma Ranbaxy Acquisition Kushagr Jain
油
Sun Pharma acquired Ranbaxy in 2014 to create the largest pharmaceutical company in India and 5th largest globally. The $4 billion all-stock deal made Sun Pharma the largest Indian pharma company in the US. It aimed to leverage Ranbaxy's generics approvals in the US and turn around its manufacturing issues. While providing synergies, the merger negatively impacted Sun Pharma's financials in the short-term due to Ranbaxy's debt and ongoing regulatory problems. The deal relieved Daiichi Sankyo of managing Ranbaxy's FDA compliance burden.Dilip Shanghvi
Dilip ShanghviMiraj Rajput
油
Dilip Shanghvi founded Sun Pharmaceuticals in 1983 with a loan of Rs. 10,000 from his father. He started the company in Kolkata and later moved headquarters to Mumbai. Sun Pharma has grown to become the fifth largest drug maker in India through strategic acquisitions both in India and abroad. Shanghvi successfully turned around loss-making companies after acquiring them. Sun Pharma focuses on specialty and niche drugs, and over 70% of its sales come from India, though it also has operations in the US.Sun pharma ranbaxy acquisition
Sun pharma ranbaxy acquisitionSai Mahesh
油
Sun Pharma acquired Ranbaxy in 2014 in a $4 billion deal to become the largest pharmaceutical company in India and fifth largest globally. The acquisition made Sun Pharma the largest Indian pharma company in the US and provided Ranbaxy with API manufacturing capabilities to resume exports to the US. However, Sun Pharma also assumed $800 million of Ranbaxy's debt and regulatory issues remain resolving quality issues at Ranbaxy's plants that were banned by the USFDA. The merger aimed to create synergies but was expected to negatively impact Sun Pharma's financial performance in the near term.Presentation on Ranbaxy's global business strategy by prashanth kumar gujja.
Presentation on Ranbaxy's global business strategy by prashanth kumar gujja.Prashanth Kumar Gujja
油
Ranbaxy Laboratories is India's largest pharmaceutical company with a worldwide presence in 49 countries. It has manufacturing locations in 8 countries and sells products in over 125 countries. Ranbaxy is among the top 10 global generic pharmaceutical companies. It has over 14,000 employees globally from 50 nationalities. In 2008, Daiichi Sankyo acquired over 51% stake in Ranbaxy Laboratories to gain access to its low-cost generic drug manufacturing capabilities and expand Daiichi's global presence. The acquisition combined Ranbaxy's strengths in generics with Daiichi's research and development expertise.Ranbaxy
RanbaxyRohit Choudhary
油
Ranbaxy is India's largest pharmaceutical company with a global presence in 43 countries. It produces generic medicines and has world-class manufacturing facilities. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse. The Indian pharmaceutical industry is the 3rd largest globally by volume and Ranbaxy is a leading player in this industry.Project Report On M & A of Ranbaxy ltd. And Daiichi sankyo
Project Report On M & A of Ranbaxy ltd. And Daiichi sankyoNikita Agarwal
油
Daiichi Sankyo acquired Ranbaxy in a deal that was expected to generate synergies by combining Daiichi Sankyo's strengths in proprietary medicines with Ranbaxy's leadership in generics. Daiichi Sankyo saw the acquisition as critical to achieving its goal of $13.1 billion in sales by 2015. Post-acquisition, Daiichi Sankyo and Ranbaxy launched a hybrid business in Brazil to expand both companies' presence in the market by having Ranbaxy support Daiichi Sankyo's subsidiary in selling branded generics, in addition to innovative drugs, while Ranbaxy's subsidiary continued independently promoting generics and entering branded generics.Gsk.
Gsk.Saikumar Gandhaphule
油
GlaxoSmithKline Consumer Healthcare Ltd is a public consumer goods company in India, part of GlaxoSmithKline plc, with a market capitalization of Rs 26,406.67 crore. Founded in 1830, it has launched several notable products and has a diverse employee base of 99,451. The company operates on both the National Stock Exchange and the Bombay Stock Exchange under specific codes.Sun Pharma Vs Lupin Pharma
Sun Pharma Vs Lupin PharmaAnmol Misal
油
This document provides information about Sun Pharmaceutical Industries Ltd and Lupin Ltd, two major pharmaceutical companies in India. It discusses their histories, goals, visions, missions, boards of directors, and key milestones. Some notable points are that Sun Pharma was established in 1983 and is now India's largest chronic prescription drug company, while Lupin was founded in 1968 and is the 3rd largest pharmaceutical company in India and 7th largest generic drug maker globally. Both companies have grown through acquRanbaxy
Ranbaxygaurav satia
油
This document discusses Ranbaxy Laboratories, a top 10 global generic drug company. It notes that Ranbaxy has a presence in over 125 countries, 2008 revenue of $1.7 billion, and over 12,000 employees from more than 50 nationalities. The document also summarizes that generic drugs have grown as a market since the 1970s due to increased lifespans, chronic diseases, and reforms aimed at reducing healthcare costs. Finally, it projects the generic drug market will grow 11-13% over the next 3-5 years.Dabur corporate-profile-august-2012
Dabur corporate-profile-august-2012Deep Rajbhandari
油
Dabur India Limited is one of the leading FMCG companies in India with a portfolio of hair care, oral care, skin care, home care, and health supplement products. It has a 125+ year history and generates over Rs. 50 billion in annual revenues. Dabur has a strong domestic and international presence across multiple categories, and its key brands such as Dabur Chyawanprash, Dabur Honey, and Odonil each generate over Rs. 1 billion in annual sales. The company aims to grow through new product development, rural expansion, and international acquisitions.GlaxoSmithKline
GlaxoSmithKlinePriyesh Waghmare
油
GlaxoSmithKline plc is a global pharmaceutical company headquartered in London, UK. It is the 3rd largest pharmaceutical company by revenue and has leading market share in anti-infectives, central nervous system, respiratory, and gastrointestinal drugs. GSK spends over $450,000 per hour on research and development and has acquired several companies in recent years to expand its product portfolio. The company's business model focuses on several therapeutic areas with respiratory, central nervous system, and vaccines being the largest segments by revenue.Dabur India Ltd.
Dabur India Ltd.Harshith Agarwal
油
Dabur India Limited is a 128-year-old Ayurvedic and FMCG company with a portfolio of over 250 herbal products. It has undergone strategic changes over four phases: initially focusing on Ayurvedic drugs, then expanding product lines and markets, restructuring under professional management to compete globally, and most recently rebranding and focusing on key brands and markets. Dabur now has annual revenues of over $600 million from consumer care, health, and international divisions, with a goal of doubling sales by 2010 through these divisions as well as foods.GSK
GSKNOMAN KHAN
油
GlaxoSmithKline is a large global pharmaceutical company formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. It is headquartered in London, England and has operations in over 100 countries. In 2009, GlaxoSmithKline had annual revenue of 贈28.4 billion and employed around 99,000 people worldwide. Key events in the company's history included the 1995 merger of Glaxo and Wellcome, the 1982 merger of SmithKline and Beckman Instruments to form SmithKline Beecham, and the 2000 merger that created GlaxoSmithKline.Product Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sAnimesh Gupta
油
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company established in 1984 that offers affordable and innovative medicines across various therapeutic areas. It has a presence in over 60 countries and key markets include India, Russia, CIS, USA, UK, South Africa, and more. The company generates revenue through global generics, active pharmaceutical ingredients, custom pharmaceutical services, new chemical entities, differentiated formulations, and biosimilars. It has research centers in India with over 1200 scientists and focuses on developing treatments for areas like cardiovascular, pain, anti-infectives, gastro-intestinal and more. Between FY2008-2012 the company saw a 13% CAGR growth in revenues.Dabur company by RAMDENI RATHNAKAR
Dabur company by RAMDENI RATHNAKAR RamdeniRathnakar
油
Dabur is India's 4th largest FMCG company with over 100 years of history. It operates in key categories like hair care, oral care, health care, skin care, home care, and foods. Dabur has 3 strategic business units: Family Products Division, Healthcare Products Division, and Ayurvedic Specialties Ltd. The company aims to maximize shareholder value by offering superior quality natural products to improve consumers' lives in personal care, health care, and foods. Dabur has a widespread presence across 50 countries and is a leader in herbal digestives with 90% market share in India.Dabur ppt satyaprakash jaiswal
Dabur ppt satyaprakash jaiswalSatyaprakash Jaiswal
油
Dabur India Ltd is India's leading FMCG company, founded in 1884 by Dr. S.K. Burman to provide effective and affordable herbal healthcare products to rural villages. It is now the 4th largest consumer goods manufacturer in India with products marketed in over 50 countries. Key products that each generate over Rs. 100 crores in revenue include Dabur Chyawanprash and Hajmola. The presentation provides an overview of Dabur's history, products, divisions, competitors and financial details.Dabur's state of duality
Dabur's state of dualitySiddharth Dasgupta
油
Dabur India Limited is a leading manufacturer of herbal and natural products in India and globally, with a history of over 100 years. It offers products across categories like healthcare, hair care, skin care, and juices. Dabur has a strong brand portfolio including Dabur, Vatika, Anmol, Real, and Hajmola. It has established a pan-India distribution network and also exports to over 50 countries. Recently, Dabur reorganized its brand strategy by focusing on 5 power brands and extending its product lines to target a wider consumer base including youth and children.Dabur india ltd. Strategic Management
Dabur india ltd. Strategic ManagementManish Sonkar
油
Dabur India Ltd is India's largest Ayurvedic medicine and natural products manufacturer, founded in 1884. It has revenues over Rs 7,680 Crore and is one of India's leading FMCG companies. Dabur's vision is dedicated to health and well-being of households, and its mission is to be a leader in natural FMCG and offer quality products and returns to stakeholders. Key competitors include Hindustan Unilever Ltd., Marico Ltd. and others. Dabur must constantly reinvent products to cope with competitor innovations and changing consumer needs.GlaxoSmithkline
GlaxoSmithklineruchi202
油
GlaxoSmithKline (GSK) is the world's second-largest pharmaceutical company, focused on improving health and quality of life through various strategic initiatives. The company's mission centers on enabling people to do more, feel better, and live longer, with a strong emphasis on product development, marketing, and ethical standards. GSK's extensive product offerings include prescription medications, vaccines, and consumer healthcare products, supported by a robust financial outlook and innovative research and development efforts.Company profile of ranbaxy
Company profile of ranbaxymanalibhardwaj
油
Ranbaxy Laboratories Limited is India's largest pharmaceutical company with a presence in 43 countries and manufacturing facilities in 8 countries. It produces affordable generic medicines and serves over 125 countries. In 2008, it entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, ranking among the top 20 global pharmaceutical companies. For 2011, it recorded global sales of $2.1 billion from both emerging and developed markets. It focuses on increasing generics business through organic and inorganic growth across geographies.Ranbaxycompanyprofile
Ranbaxycompanyprofile bhawna allagh
油
Ranbaxy is India's largest pharmaceutical company with a global footprint in 43 countries. It has a diverse product portfolio and strong R&D capabilities. In 2011, Ranbaxy recorded global sales of $2.1 billion, with emerging and developed markets each contributing around 47% and 46% respectively. Ranbaxy aims to grow organically and inorganically, focusing on high-growth areas like biologics and injectables. It also has a hybrid business model through its alliance with Daiichi Sankyo to create an innovator and generic powerhouse. Ranbaxy emphasizes R&D as a strategic priority and has over 1,200 personnel dedicated to research.Ranbaxy global strategy for growth
Ranbaxy global strategy for growthVirendra Shukla
油
Ranbaxy Laboratories Ltd. was Indias largest pharmaceutical company in 2006, with global revenue of $1.3 billion. The document discusses Ranbaxy's history and growth strategy under different CEOs from the 1990s-2000s. It summarizes how Parvinder Singh expanded internationally through acquisitions and joint ventures, establishing manufacturing facilities around the world. His successors Devinder Singh Brar and Brian W Tempest continued the global strategy, further growing international sales especially in the US through generic drugs.PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
油
The Indian pharmaceutical industry has significantly evolved since the 1960s, driven by government support and economic liberalization, growing to a $20 billion industry by 2015. The sector is largely dominated by bio-pharmaceuticals, contributing 62% of total revenue and witnessing a robust export growth of 26.1%. Despite challenges such as market pressures and the need for organizational transformation, the industry is expected to continue expanding with new drug developments and rising demands.Shasun Pharmaceuticals
Shasun PharmaceuticalsKarthik Varma
油
Shasun Pharmaceuticals is an Indian pharmaceutical company established in 1976. It generates revenue primarily from active pharmaceutical ingredients (API), contract research and medical services (CRAMS), and finished dosage formulations. API contributes 55% of total revenue. The company has a strong presence in North America, Europe, and Japan and is expanding in Korea and Brazil. It has filed several drug master files and has the highest number of manufacturing facilities approved by the USFDA outside of the U.S. CRAMS contributes 45% of consolidated revenue through formulation research and clinical trials. The company is also pursuing biotechnology and filed 15 ANDAs in FY2015. Recent news showed doubled quarterly profits in Q4 FY2015 compared to theThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalAnup Soans
油
Mankind Pharma has experienced significant growth since its establishment in 1991, focusing on high-value OTC products and recently introducing a generic version of dydrogesterone, expected to generate substantial revenue. The company's unique marketing strategy involves comprehensive engagement with healthcare professionals and retaining a loyal workforce, resulting in low employee attrition and consistent sales efforts. Mankind's expansion includes international markets and entry into diagnostics, positioning the company as a notable player in the pharmaceutical industry with ambitious revenue targets for future fiscal years.Pharmaceutical industry in india
Pharmaceutical industry in indiaSahil Khanna
油
The pharmaceutical industry in India is the third largest in the world by volume. It has grown significantly since the 1960s and now holds a market share of $14 billion in the US. Exports of pharmaceutical products from India have grown at a compound annual rate of 21.25% between 2006-07 and 2008-09. Ranbaxy Laboratories is a major Indian pharmaceutical company with global sales of over $1 billion in 2006. It has manufacturing facilities in several countries and markets drugs in over 125 countries. The Indian pharmaceutical industry is poised for continued growth and increasing global market share in the coming years.Pharma industry
Pharma industryBestha Chakri
油
The document discusses the top 15 pharmaceutical companies in India based on overall revenue. Sun Pharmaceuticals is the largest, generating INR 273.28 billion in revenue in FY 2018, followed by Aurobindo Pharma and Lupin. It provides details on the year founded, business segments, top markets, and revenue for FY 2018 for each of the top 15 companies, including Sun Pharma, Aurobindo Pharma, Lupin, Cipla, Dr. Reddy's Laboratories, Cadila Healthcare, Intas Pharmaceuticals, Glenmark Pharma, Torrent Pharmaceuticals, ManKind Pharma, Biocon, Piramal Enterprises, Wockhardt, Divis LaboratoriesRanbaxy company profile
Ranbaxy company profilesanath_mahadi
油
Ranbaxy is India's largest pharmaceutical company, producing generic medicines for over 125 countries. It was founded in 1961 and went public in 1973. Ranbaxy has a global footprint with manufacturing facilities in 8 countries and offices in 43 countries. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, now ranking among the top 20 pharmaceutical companies globally. Ranbaxy's mission is to enrich lives globally with quality and affordable pharmaceuticals.More Related Content
What's hot (13)
Gsk.
Gsk.Saikumar Gandhaphule
油
GlaxoSmithKline Consumer Healthcare Ltd is a public consumer goods company in India, part of GlaxoSmithKline plc, with a market capitalization of Rs 26,406.67 crore. Founded in 1830, it has launched several notable products and has a diverse employee base of 99,451. The company operates on both the National Stock Exchange and the Bombay Stock Exchange under specific codes.Sun Pharma Vs Lupin Pharma
Sun Pharma Vs Lupin PharmaAnmol Misal
油
This document provides information about Sun Pharmaceutical Industries Ltd and Lupin Ltd, two major pharmaceutical companies in India. It discusses their histories, goals, visions, missions, boards of directors, and key milestones. Some notable points are that Sun Pharma was established in 1983 and is now India's largest chronic prescription drug company, while Lupin was founded in 1968 and is the 3rd largest pharmaceutical company in India and 7th largest generic drug maker globally. Both companies have grown through acquRanbaxy
Ranbaxygaurav satia
油
This document discusses Ranbaxy Laboratories, a top 10 global generic drug company. It notes that Ranbaxy has a presence in over 125 countries, 2008 revenue of $1.7 billion, and over 12,000 employees from more than 50 nationalities. The document also summarizes that generic drugs have grown as a market since the 1970s due to increased lifespans, chronic diseases, and reforms aimed at reducing healthcare costs. Finally, it projects the generic drug market will grow 11-13% over the next 3-5 years.Dabur corporate-profile-august-2012
Dabur corporate-profile-august-2012Deep Rajbhandari
油
Dabur India Limited is one of the leading FMCG companies in India with a portfolio of hair care, oral care, skin care, home care, and health supplement products. It has a 125+ year history and generates over Rs. 50 billion in annual revenues. Dabur has a strong domestic and international presence across multiple categories, and its key brands such as Dabur Chyawanprash, Dabur Honey, and Odonil each generate over Rs. 1 billion in annual sales. The company aims to grow through new product development, rural expansion, and international acquisitions.GlaxoSmithKline
GlaxoSmithKlinePriyesh Waghmare
油
GlaxoSmithKline plc is a global pharmaceutical company headquartered in London, UK. It is the 3rd largest pharmaceutical company by revenue and has leading market share in anti-infectives, central nervous system, respiratory, and gastrointestinal drugs. GSK spends over $450,000 per hour on research and development and has acquired several companies in recent years to expand its product portfolio. The company's business model focuses on several therapeutic areas with respiratory, central nervous system, and vaccines being the largest segments by revenue.Dabur India Ltd.
Dabur India Ltd.Harshith Agarwal
油
Dabur India Limited is a 128-year-old Ayurvedic and FMCG company with a portfolio of over 250 herbal products. It has undergone strategic changes over four phases: initially focusing on Ayurvedic drugs, then expanding product lines and markets, restructuring under professional management to compete globally, and most recently rebranding and focusing on key brands and markets. Dabur now has annual revenues of over $600 million from consumer care, health, and international divisions, with a goal of doubling sales by 2010 through these divisions as well as foods.GSK
GSKNOMAN KHAN
油
GlaxoSmithKline is a large global pharmaceutical company formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. It is headquartered in London, England and has operations in over 100 countries. In 2009, GlaxoSmithKline had annual revenue of 贈28.4 billion and employed around 99,000 people worldwide. Key events in the company's history included the 1995 merger of Glaxo and Wellcome, the 1982 merger of SmithKline and Beckman Instruments to form SmithKline Beecham, and the 2000 merger that created GlaxoSmithKline.Product Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sAnimesh Gupta
油
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company established in 1984 that offers affordable and innovative medicines across various therapeutic areas. It has a presence in over 60 countries and key markets include India, Russia, CIS, USA, UK, South Africa, and more. The company generates revenue through global generics, active pharmaceutical ingredients, custom pharmaceutical services, new chemical entities, differentiated formulations, and biosimilars. It has research centers in India with over 1200 scientists and focuses on developing treatments for areas like cardiovascular, pain, anti-infectives, gastro-intestinal and more. Between FY2008-2012 the company saw a 13% CAGR growth in revenues.Dabur company by RAMDENI RATHNAKAR
Dabur company by RAMDENI RATHNAKAR RamdeniRathnakar
油
Dabur is India's 4th largest FMCG company with over 100 years of history. It operates in key categories like hair care, oral care, health care, skin care, home care, and foods. Dabur has 3 strategic business units: Family Products Division, Healthcare Products Division, and Ayurvedic Specialties Ltd. The company aims to maximize shareholder value by offering superior quality natural products to improve consumers' lives in personal care, health care, and foods. Dabur has a widespread presence across 50 countries and is a leader in herbal digestives with 90% market share in India.Dabur ppt satyaprakash jaiswal
Dabur ppt satyaprakash jaiswalSatyaprakash Jaiswal
油
Dabur India Ltd is India's leading FMCG company, founded in 1884 by Dr. S.K. Burman to provide effective and affordable herbal healthcare products to rural villages. It is now the 4th largest consumer goods manufacturer in India with products marketed in over 50 countries. Key products that each generate over Rs. 100 crores in revenue include Dabur Chyawanprash and Hajmola. The presentation provides an overview of Dabur's history, products, divisions, competitors and financial details.Dabur's state of duality
Dabur's state of dualitySiddharth Dasgupta
油
Dabur India Limited is a leading manufacturer of herbal and natural products in India and globally, with a history of over 100 years. It offers products across categories like healthcare, hair care, skin care, and juices. Dabur has a strong brand portfolio including Dabur, Vatika, Anmol, Real, and Hajmola. It has established a pan-India distribution network and also exports to over 50 countries. Recently, Dabur reorganized its brand strategy by focusing on 5 power brands and extending its product lines to target a wider consumer base including youth and children.Dabur india ltd. Strategic Management
Dabur india ltd. Strategic ManagementManish Sonkar
油
Dabur India Ltd is India's largest Ayurvedic medicine and natural products manufacturer, founded in 1884. It has revenues over Rs 7,680 Crore and is one of India's leading FMCG companies. Dabur's vision is dedicated to health and well-being of households, and its mission is to be a leader in natural FMCG and offer quality products and returns to stakeholders. Key competitors include Hindustan Unilever Ltd., Marico Ltd. and others. Dabur must constantly reinvent products to cope with competitor innovations and changing consumer needs.GlaxoSmithkline
GlaxoSmithklineruchi202
油
GlaxoSmithKline (GSK) is the world's second-largest pharmaceutical company, focused on improving health and quality of life through various strategic initiatives. The company's mission centers on enabling people to do more, feel better, and live longer, with a strong emphasis on product development, marketing, and ethical standards. GSK's extensive product offerings include prescription medications, vaccines, and consumer healthcare products, supported by a robust financial outlook and innovative research and development efforts.Similar to Ranabaxy pharama copy (20)
Company profile of ranbaxy
Company profile of ranbaxymanalibhardwaj
油
Ranbaxy Laboratories Limited is India's largest pharmaceutical company with a presence in 43 countries and manufacturing facilities in 8 countries. It produces affordable generic medicines and serves over 125 countries. In 2008, it entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, ranking among the top 20 global pharmaceutical companies. For 2011, it recorded global sales of $2.1 billion from both emerging and developed markets. It focuses on increasing generics business through organic and inorganic growth across geographies.Ranbaxycompanyprofile
Ranbaxycompanyprofile bhawna allagh
油
Ranbaxy is India's largest pharmaceutical company with a global footprint in 43 countries. It has a diverse product portfolio and strong R&D capabilities. In 2011, Ranbaxy recorded global sales of $2.1 billion, with emerging and developed markets each contributing around 47% and 46% respectively. Ranbaxy aims to grow organically and inorganically, focusing on high-growth areas like biologics and injectables. It also has a hybrid business model through its alliance with Daiichi Sankyo to create an innovator and generic powerhouse. Ranbaxy emphasizes R&D as a strategic priority and has over 1,200 personnel dedicated to research.Ranbaxy global strategy for growth
Ranbaxy global strategy for growthVirendra Shukla
油
Ranbaxy Laboratories Ltd. was Indias largest pharmaceutical company in 2006, with global revenue of $1.3 billion. The document discusses Ranbaxy's history and growth strategy under different CEOs from the 1990s-2000s. It summarizes how Parvinder Singh expanded internationally through acquisitions and joint ventures, establishing manufacturing facilities around the world. His successors Devinder Singh Brar and Brian W Tempest continued the global strategy, further growing international sales especially in the US through generic drugs.PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
油
The Indian pharmaceutical industry has significantly evolved since the 1960s, driven by government support and economic liberalization, growing to a $20 billion industry by 2015. The sector is largely dominated by bio-pharmaceuticals, contributing 62% of total revenue and witnessing a robust export growth of 26.1%. Despite challenges such as market pressures and the need for organizational transformation, the industry is expected to continue expanding with new drug developments and rising demands.Shasun Pharmaceuticals
Shasun PharmaceuticalsKarthik Varma
油
Shasun Pharmaceuticals is an Indian pharmaceutical company established in 1976. It generates revenue primarily from active pharmaceutical ingredients (API), contract research and medical services (CRAMS), and finished dosage formulations. API contributes 55% of total revenue. The company has a strong presence in North America, Europe, and Japan and is expanding in Korea and Brazil. It has filed several drug master files and has the highest number of manufacturing facilities approved by the USFDA outside of the U.S. CRAMS contributes 45% of consolidated revenue through formulation research and clinical trials. The company is also pursuing biotechnology and filed 15 ANDAs in FY2015. Recent news showed doubled quarterly profits in Q4 FY2015 compared to theThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalAnup Soans
油
Mankind Pharma has experienced significant growth since its establishment in 1991, focusing on high-value OTC products and recently introducing a generic version of dydrogesterone, expected to generate substantial revenue. The company's unique marketing strategy involves comprehensive engagement with healthcare professionals and retaining a loyal workforce, resulting in low employee attrition and consistent sales efforts. Mankind's expansion includes international markets and entry into diagnostics, positioning the company as a notable player in the pharmaceutical industry with ambitious revenue targets for future fiscal years.Pharmaceutical industry in india
Pharmaceutical industry in indiaSahil Khanna
油
The pharmaceutical industry in India is the third largest in the world by volume. It has grown significantly since the 1960s and now holds a market share of $14 billion in the US. Exports of pharmaceutical products from India have grown at a compound annual rate of 21.25% between 2006-07 and 2008-09. Ranbaxy Laboratories is a major Indian pharmaceutical company with global sales of over $1 billion in 2006. It has manufacturing facilities in several countries and markets drugs in over 125 countries. The Indian pharmaceutical industry is poised for continued growth and increasing global market share in the coming years.Pharma industry
Pharma industryBestha Chakri
油
The document discusses the top 15 pharmaceutical companies in India based on overall revenue. Sun Pharmaceuticals is the largest, generating INR 273.28 billion in revenue in FY 2018, followed by Aurobindo Pharma and Lupin. It provides details on the year founded, business segments, top markets, and revenue for FY 2018 for each of the top 15 companies, including Sun Pharma, Aurobindo Pharma, Lupin, Cipla, Dr. Reddy's Laboratories, Cadila Healthcare, Intas Pharmaceuticals, Glenmark Pharma, Torrent Pharmaceuticals, ManKind Pharma, Biocon, Piramal Enterprises, Wockhardt, Divis LaboratoriesRanbaxy company profile
Ranbaxy company profilesanath_mahadi
油
Ranbaxy is India's largest pharmaceutical company, producing generic medicines for over 125 countries. It was founded in 1961 and went public in 1973. Ranbaxy has a global footprint with manufacturing facilities in 8 countries and offices in 43 countries. In 2008, Ranbaxy entered an alliance with Daiichi Sankyo to create an innovator and generic pharmaceutical powerhouse, now ranking among the top 20 pharmaceutical companies globally. Ranbaxy's mission is to enrich lives globally with quality and affordable pharmaceuticals.Sun pharmaceutical ( international marketing ) term paper
Sun pharmaceutical ( international marketing ) term paperAniruddha Vashishtha
油
This document provides a summary of the history and growth of Sun Pharmaceutical Industries Ltd., one of the largest pharmaceutical companies in the world. It was founded in 1983 in India by Dilip Shanghvi and started with 5 psychiatry products. Over the decades, it has expanded significantly through acquisitions and new facilities, becoming a global leader in generic and branded generics drugs with a presence worldwide. Key acquisitions and events that fueled its growth include Ranbaxy in 2014, Caraco Pharmaceutical in 2004, and other companies, expanding its product portfolio and global reach.Ranbaxy laboratories project
Ranbaxy laboratories projectNandita Sadani
油
Ranbaxy Laboratories is an international pharmaceutical company headquartered in India. It manufactures generic and branded generic drugs and has manufacturing facilities in several countries. The document discusses Ranbaxy's business overview, financial performance from 2004-2008, demand forecasting for 2010, and recommendations. Ranbaxy's sales grew from 2004-2008 but it reported a net loss in 2008 due to issues with the US FDA and forex losses. Demand forecasting using a linear trend line model estimates Ranbaxy's sales in 2010 will be approximately Rs. 47,315.20 crores.Ranbaxy
RanbaxyChaitanya Salunke
油
Ranbaxy is an international pharmaceutical company with over 50 years of experience. It has a presence in over 150 countries and 16 manufacturing facilities across 8 countries. Ranbaxy develops, manufactures, and markets generic, branded generic, and over-the-counter drugs across multiple therapies, with a portfolio of over 500 molecules. It focuses on research and development to provide high-quality yet affordable treatment options.DRL Vs Ranbaxy Pharmaceutical Gaints.pptx
DRL Vs Ranbaxy Pharmaceutical Gaints.pptxAnshumanTripathy14
油
DRL Vs Ranbaxy Pharmaceutical Gaints.pptxNovartis
Novartissunilngupta
油
The pharmaceutical industry in India is sized at $5 billion currently ranked 4th in terms of volume and 13th in terms of value, growing at an annual rate of 14.3% and expected to reach $25 billion by 2010. There are over 23,000 pharma companies in India but only around 300 operate in the organized sector. Novartis India is a 51% subsidiary of Swiss company Novartis, established in India in 1996. Novartis India's pharmaceuticals business contributes 62% of its sales and it has grown its total income over the years from 2004-2007 but profitability has been impacted by price regulations in India.Sun Pharmaceuticals is one of India's largest pharmaceutical companies, speci...
Sun Pharmaceuticals is one of India's largest pharmaceutical companies, speci...dineshwhatsapp2020
油
This PPT is about Sun pharmaceuticals and its financial analysis and active pharmaceutical ingredients (APIs). Founded in 1983 by Dilip Shanghvi, it operates in over 100 countries. The company focuses on neurology, cardiology, diabetology, and dermatology, with key acquisitions like Ranbaxy strengthening its global presence.Study On Pharmaceuticals Companies
Study On Pharmaceuticals CompaniesVarsha Chauhan
油
The document provides an overview of the pharmaceutical industry in India and details regarding Sun Pharma and Lupin, two major Indian pharmaceutical companies. It discusses the regulatory environment, business models, financial performance, acquisitions, and growth strategies of Sun Pharma and Lupin. The summary highlights both companies' focus on expanding their global footprint and specialty product portfolios through acquisitions and internal research and development.Sun pharma
Sun pharmaRavinder Sharma
油
Sun Pharmaceutical Industries was founded in 1983 in Kolkata, India by Dilip Shanghvi. It has since grown to become one of the largest pharmaceutical companies in India through strategic acquisitions and a focus on generic drugs. Some key milestones include acquiring Caraco Pharmaceutical Labs in 1997, acquiring a plant in Ohio in 2005, and merging with Ranbaxy Laboratories in 2014. Sun Pharma has a presence across multiple therapeutic areas and geographic regions. It has a market share of 3.2% in India and follows strict regulatory guidelines. With the aging global population and rising incomes, Sun Pharma is well positioned for continued growth in the coming years through synergies from acquisitions and expanding in emerging marketsLupin Corporate Small
Lupin Corporate Smallvenkychetty
油
Lupin is an Indian pharmaceutical company with the mission to become an innovation-led transnational company. Their goal is to achieve $1 billion in sales by 2009. They have a diverse business portfolio including APIs, finished dosages, novel drug delivery systems, and new drug discovery. Lupin has strong R&D and manufacturing capabilities and is a leader in anti-TB products and cephalosporins. Their business model focuses on backward integration, global presence, niche areas through R&D, and cost-effective therapies.Sun pharma acquires ranbaxy
Sun pharma acquires ranbaxyMaster Verma
油
Sun Pharmaceuticals acquired Ranbaxy in a $4 billion all-share deal in 2014. This created the fifth largest specialty generics company in the world. The merger strengthened Sun Pharma's global footprint, distribution network, and portfolio in key therapeutic areas. It gained access to Ranbaxy's brands and markets in regions like the US, Europe, Brazil, Russia, and China. However, Ranbaxy had been struggling financially prior to the acquisition due to regulatory and legal issues.Sunpharma-Ranbaxy aquisition
Sunpharma-Ranbaxy aquisitionYadnesh Shinde
油
Sun Pharmaceutical Industries acquired Ranbaxy Laboratories in an all-stock deal valued at $4 billion, creating the largest pharmaceutical company in India. Under the terms of the deal, Ranbaxy shareholders received 0.8 shares of Sun Pharma for each Ranbaxy share owned. The combined company will have annual revenues of $4.2 billion and EBITDA of $1.2 billion, making it the fifth largest generics company globally. The acquisition helps Sun Pharma gain Ranbaxy's pipeline of drugs awaiting FDA approval and expands its global footprint, while allowing Daiichi Sankyo to exit its troubled investment in Ranbaxy. However, integrating Ranbaxy's manufacturing facilities, which are currently banned byAd
Recently uploaded (20)
Extending Infrastructure Life with Protective Coatings
Extending Infrastructure Life with Protective Coatingsrahil wit
油
Protective coatings play a vital role in safeguarding bridges and infrastructure from environmental damage. By forming a durable barrier against moisture, chemicals, and UV radiation, these coatings help prevent corrosion and structural degradation. This reduces maintenance costs and extends the service life of critical assets.
Source - https://witmansgroup.com/how-protective-coatings-enhance-the-longevity-of-bridges-and-infrastructure/Podcast Show Notes - Rapid International Expansion for Scale-up Stage Tech Bu...
Podcast Show Notes - Rapid International Expansion for Scale-up Stage Tech Bu...Dave Litwiller
油
Considerations for rapid international expansion of scale-up stage technology businessesOleksandr Osypenko: 仂仄仆从舒 仗仂从 (UA)
Oleksandr Osypenko: 仂仄仆从舒 仗仂从 (UA)Lviv Startup Club
油
Oleksandr Osypenko: 仂仄仆从舒 仗仂从 (UA)
LemBS PMP Prep Course
Website https://lembs.com/pmpcourse
Youtube https://www.youtube.com/startuplviv
FB https://www.facebook.com/pmdayconferenceIEA_Press_Release_Tullow_Agreement-16-6-2025-1.pdf
IEA_Press_Release_Tullow_Agreement-16-6-2025-1.pdfbusinessweekghana
油
Dont extend petroleum licenses of Tullow IEA appeals to Govtsolulab.com-Build Domain-Specific LLMs Step-by-Step Blueprint.pdf
solulab.com-Build Domain-Specific LLMs Step-by-Step Blueprint.pdfcelinedion89121
油
https://www.solulab.com/large-language-model-development-company/?utm_source=PDFSubmission+&utm_medium=CelineDionThe Role of Business Process Tools in Driving Strategic Agility
The Role of Business Process Tools in Driving Strategic AgilityRUPAL AGARWAL
油
This presentation explores how modern business process tools empower organizations to adapt quickly to change, align operations with strategic goals, and enhance decision-making. Learn how BPM software, workflow automation, and real-time analytics support agility in a rapidly evolving business landscape.Programmatic Advertising in Healthcare - Harvee Health.pptx
Programmatic Advertising in Healthcare - Harvee Health.pptxhealthcareharvee
油
Discover how programmatic advertising transforms healthcare marketing with precision targeting, real examples, ROI data, and expert strategies for success. For more info visit: https://www.harveehealthcare.com/blog/what-is-programmatic-advertising-how-to-use-it-in-healthcare/The Innovative Cybersecurity Leaders Driving Business Growth in 2025.pdf
The Innovative Cybersecurity Leaders Driving Business Growth in 2025.pdfciolook1
油
It is in this scenario that Dr Harsha E Thennarasu (a first Doctorate in the field of Cybersecurity), who is the Founder and Chief IT Security Advisor of HKIT Security Solutions, Bangalore, emerges as one of the most innovative cybersecurity leaders driving business growth in 2025.
The Ultimate Guide to Print on Demand Apparel.docx
The Ultimate Guide to Print on Demand Apparel.docxAesthetic Bk
油
Print-on-demand (POD) apparel is a business model where custom t-shirts, hoodies, hats, and more are printed only when someone places an order. Its a favorite for startups, influencers, and artists who want to launch custom t-shirt printing or print-on-demand clothing lines online. With POD, you simply upload your design, choose your product, and a third-party supplier handles printing, packing, and shipping.
Kenyan Msme Export Book by Dickens Aluha Mujumba
Kenyan Msme Export Book by Dickens Aluha MujumbaJoshuaKihara
油
A guide for micro-enterprises in Kenya who want to venture into export businessBOURNS POTENTIOMETER Provide You Precision
BOURNS POTENTIOMETER Provide You Precisionsmidmart
油
Bourns potentiometers are high-quality variable resistors designed for precision control in a wide range of electronic applications. Known for their durability, accuracy, and reliability, Bourns potentiometers are ideal for adjusting signal levels, tuning circuits, or setting reference voltages in industrial, automotive, and consumer electronics.
Available in rotary and slide variants, these components offer excellent repeatability, smooth operation, and long mechanical life, making them a trusted choice for engineers and designers worldwide.
Built with our sleeves rolled upAction
Built with our sleeves rolled upActionAction EDI
油
Some stories start with pitch decks, seed funding, and big VC buzz.
Ours? It started with a frustrated customer, a whiteboard, and a promise.
We were visiting a long-time clientjust a routine check-in.
But in passing, they said something that stopped us cold:
We hate our EDI software. But were stuck with it.
They werent a small team. They were moving high volumes with a recognizable brand.
And yet they were spending hours wrestling with outdated tools, error-prone processes, and support that never picked up the phone.
We knew EDI wasnt supposed to feel like a trap.
So we stayed.
Not for a few hoursbut for a week.
We sat with their ops team. Watched their workflows. Felt their friction firsthand.
And at the end of that week, the decision was obvious:
Build something better.
鏝 Build it for the people who do the work.
And back it with real support.
Thats how ActionEDI was bornnot to chase a trend, but to solve the exact problem too many small and mid-sized businesses were silently dealing with.
Today, weve processed over 5 million transactions.
We support partners like CDW, Volvo, and John Deere.
And were just getting started.
Because when you build with your sleeves rolled up,
You dont forget who youre building it for.
https://actionedi.com/25 Surprising Insights That Prove Microlearning Is the Future of Training.pdf
25 Surprising Insights That Prove Microlearning Is the Future of Training.pdfMaxLearn LLC
油
Are you struggling to find ways to train your employees without keeping them away from the work? Have you ever given thought to using microlearning? Do youBuilding a Customer-Centric Business Best Practices.pdf
Building a Customer-Centric Business Best Practices.pdfStacy Neir
油
In todays competitive marketplace, businesses must prioritize their customers if they want to succeed. A customer-centric approach means putting the needs, preferences, and experiences of your customers at the forefront of your business strategy. By building a customer-centric business, you can foster stronger relationships, increase customer loyalty, and drive long-term growth. Here are some best practices for developing a customer-centric business that puts your customers at the heart of everything you do.
Breaking Through Cultural Friction: The Role of Respect for People (Strengthe...
Breaking Through Cultural Friction: The Role of Respect for People (Strengthe...KaiNexus
油
Presented by
Scott Gauvin
CEO of Macresco Consulting and the Co-founder of the Respect for People Roadmap
Learning objectives:
- Identify the hidden barriers that prevent Lean from gaining tractionand discover practical strategies to overcome them
- Learn the nine behaviors leaders and employees can adopt to build a culture of continuous improvement
- Gain strategic insights into driving cultural change across teams and entire organizations
Scott Gauvin is the CEO of Macresco Consulting and the Co-founder of the Respect for People Roadmap. With 30 years of experience in operations, he has helped organizations around the world and across industries rethink the path to transformationnot just in process, but in mindset.
A contributing author to Leading With Compassion: Cultivating Connection from the Inside Out, Scott believes real change happens when organizations bridge the gap between culture and strategy. Right now, hes focused on helping organizations unlock performance by systematically cultivating the behaviors that make it possible.
Power of the Many Masterclasses - 2nd draft .pptx
Power of the Many Masterclasses - 2nd draft .pptxAlexBausch2
油
Masterclass on digitalisation of Energy SystemsIan McAllister - Respected Photographer And Writer
Ian McAllister - Respected Photographer And WriterIan McAllister
油
Ian McAllister, a highly respected photographer, and writer, has dedicated his life's work to raising awareness about the fragile ecosystems of the Great Bear Rainforest. His compelling imagery and insightful narratives have garnered international acclaim and have been featured in prestigious publications like National Geographic. McAllister's ability to capture nature's intricate beauty has brought attention to the plight of endangered species and inspired individuals worldwide to join the fight for conservation.Ad
Ranabaxy pharama copy
- 1. RANABAXY PHARAMAI B C S M B A PREPAIRED BY-JOYTI RANJAN SUNDARAYA
- 2. CORPORATE HEAD OFFICE, GURGAON
- 3. Mr Atul Sobti MD & CEO OF RANBAXY
- 4. INTRDOUCTIONRanbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse
- 5. Mission & VisionTo become a research based International pharmaceutical company.VISSION-2012Achieve significant business with a strong presence in developed market.
- 6. R & DDedicated Fascility for Innovative and Genirics Research.
- 7. 1400 R &D Personnel(~300 Doctorates.)
- 8. Highest R & D spender across industry.
- 9. R & D collabaraation.Corporate social ResponsibilityAn essential component of Ranbaxy's CSR is to care for the community. Ranbaxy Rural Development Trust in 1978 setupBased on the theme Health For Alllater re-christened as Ranbaxy Community Health Care Society in 1994. Operates in the states of Punjab, Haryana, H.P.,MP.and Delhi /Gurgaon to provide integrated health care to about 2 lakh people staying in 100 villages and urban slum areas..
- 10. FinancialsRanbaxy was incorporated in 1961 and went public in 1973. For the year 2009, the Company recorded Global Sales of US $ 1519 Mn. The Company has a balanced mix of revenues from emerging and developed markets that contribute 54% and 39% respectively. In 2009, North America, the Company's largest market contributed sales of US $ 397 Mn, followed by Europe garnering US $ 269 Mn and Asia clocking sales of around US $ 441
- 11. StrategyRanbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. Growth is well spread across geographies with focus on emerging markets. The Company continues to evaluate acquisition opportunities in India, emerging and developed markets to strengthen its business and competitiveness. Ranbaxy has forayed into high growth potential segments like Biologics, Oncology and Injectables. These new growth areas will add significant depth to the existing product pipeline.
- 12. Current market shareMarket Share of Ranbaxy The Company is currently ranked 2nd in the Indian pharmaceutical market with 4.98% market share (IMS, Oct-Dec09). Global sales in 2009 were USD 1,519 Mn (Rs. 73,441 Mn), De-growth of 9% over previous year. In Rupee terms, sales grew moderately by 1%. Sales during the Quarter recorded growth of 25% at USD 482 Mn (Rs. 22,699 Mn). Emerging markets accounted for 54% of sales during the year, while developed markets contributed
- 13. Ranbaxy Top productsSimvastainControl hypercholesterolemia and to prevent cardiovascular disease.AmoxiClav potassiumUsed to treat a broad spectrum of bacterial infections.Isotretinoin. for the treatment of brain cancer.Ciprofloxacin.It kills bacteria by interfering.OmeprazoleUsed in the treatment of dyspepsia
- 14. MAJOR COMPETITOR COMPANIESTOTAL ASSETS ( Cr. ) SUN PHARMA 5.747.47DR Reedy labs 6,477,80CIPLA 5,919,16RANBAXY 7,482,99LUPIN 3,437,36GlaxoSmithKline 1,764,57Cadillac Health 2,216,20Primal Health 2,527,81Glen mark 2,527,93
- 15. Ranbaxy H1 2010 Sales by Market
- 16. Ranbaxy Sales by Geography
- 17. Major Achievements of RanbaxyIndia's largest pharmaceutical company. Received The Economic Times Award for Corporate Excellence for 'The Company of the Year 2002-2003'. Ranbaxy is among the elite club of Million Dollar Companies. Ranbaxy received India's first approval from USFDA for an Anti Retroviral (ARV) drug under the U.S. President's Emergency Plan for AIDS Relief.
- 18. THANKYOU